期刊文献+

^(125)I-USPIO-bevacizumab用于肝细胞肝癌的SPECT/CT/MRI多模态显像研究 被引量:1

Rearch of ^(125)I-USPIO-Bevacizumab for Hepatocellular Carcinoma SPECT/CT/MRI Imaging
下载PDF
导出
摘要 目的:探讨125I标记的超小超顺磁性氧化铁颗粒(ultrasmall superparamagnetic iron oxide,USPIO)偶联的贝伐珠单抗(bevacizumab)用于HepG2肝细胞肝癌模型鼠多模态显像的可行性。方法:用125I标记bevacizumab,将其经尾静脉注射入HepG2肝细胞癌肝模型鼠,注射后2 h和24 h分别进行小动物活体SPECT/CT显像。然后,用直径小于20 nm的USPIO偶联bevacizumab,合成USPIO-bevacizumab;用125I标记USPIO-bevacizumab形成125I-USPIO-bevacizumab,将其经尾静脉注射入HepG2肝细胞癌模型鼠;注射后2 h和24 h分别行小动物SPECT/CT显像。显像结束后,处死模型鼠,采用免疫组化实验验证放射性标记的纳米颗粒的靶向性。为了验证USPIO-bevacizumab用于MRI显像的效果,将未用125I标记的USPIO-bevacizumab从尾静脉注射到到1只HepG2肝细胞癌模型鼠,分别于注射前后行活体MRI T2 WI加权显像。结果:125I-bevacizumab注射后,HepG2肝细胞癌模型鼠的Nano SPECT/CT显像及感兴趣区(ROI)定量分析显示,肿瘤的放射性吸收在2 h及24h分别为2.3%和2.5%,放射标志物集中在肿瘤边缘;而125I-USPIO-bevacizumab注射后,模型鼠肿瘤的放射性吸收在2 h及24 h分别为0.54%和1.04%,放射标志物在实体瘤呈均匀分布。肝细胞癌模型鼠MRI T2 WI加权MRI成像显示,注射显像剂后,肝脏及肿瘤部位信号均较注射前轻微减弱。免疫组化显示,HepG2肿瘤组织中有血管内皮生长因子(VEGF)的阳性表达及新生血管形成。结论:125I-USPIO-bevacizumab对HepG2肝细胞肝癌组织具有较好的生物靶向性,可作为新型双模态分子影像探针应用于肝细胞肝癌的SPECT/MRI显像研究。 Objective:To explore the feasibility of bevacizumab conjugated with 125I labeled ultrasmall superparamagnetic iron oxide (USPIO) for HepG2 tumor imaging.Methods:Firstly,bevacizumab was labeled with 125I and injected into the tail vein of a mouse with HepG2-induced hepatocellular carcinoma,and microSPECT/CT scannings were performed at 2 h and 24 h post injection.Then,bevacizumab was conjugated to USPIO with diameters less than 20 nm and then labeled with 125I.The 125I-USPIO-bevacizumab was injected into the tail vein of a mouse with HepG2-induced hepatocellular carcinoma,and microSPECT/CT scannings were performed at 2 h and 24 h after injection.After imaging,the mouse was sacrificed and the tumor was removed for immunohistological study to verify the targeting capability of 125I-USPIO-bevacizumab.Additionally,in order to test the potential of USPIO-bevacizumab as a MRI imaging probe,another one HepG2 tumored mouse was performed MRI T2WI imaging before and after injection of this probe.Results:SPECT/CT imaging of HepG2 tumored mice showed that the radioactivity of 125I-bevacizumab accumulated at the edge of the tumor; ROI analysis of tumor showed 2.3% at 2 h and 2.5% at 24 h,respectively.However,125I-USPIO-bevacizumab accumulated evenly in the tumor area with ROI of 0.54% at 2 h and 1.04% at 24 h.T2 weighted imaging by 3T Trio MRI revealed slightly darker signal in the tumor area after USPIO-bevacizumab was given to HepG2 tumored mouse than before.Expression of vascular endothelial growth factor of (VEGF) was detected in the HepG2 tumor and new vessels were also found by immunohistology.Conclusions:The 125I-USPIO-bevacizumab have good targeting capacity to HepG2 hepatocellular carcinoma,and it may be a potential novel hybrid SPECT/MRI probe for hepatocellular carcinoma imaging.
出处 《中国临床医学》 2013年第6期828-832,共5页 Chinese Journal of Clinical Medicine
基金 国家自然科学基金青年基金项目(编号:81201130) 上海市影像医学研究所基金项目(编号:Y-2013-11)
关键词 125I 超顺磁性氧化铁纳米颗粒 贝伐珠单抗 肝细胞肝癌 多模态呈像 125I Ultrasmall superparamagnetic iron oxide Bevacizumab Hepatocellular Carcinoma Muli-modalimaging
  • 相关文献

参考文献11

  • 1Farinati F,Sergio A,Baldan A,et al.Early and very early hepatocellular carcinoma:when and how much do staging and choice of treatment really matter? A multi-center study[J].BMC Cancer,2009,9:33.
  • 2Tang ZY.Small hepatocellular carcinom:current status and prospect[J].Hepatobiliary Pancreat Dis Int,2002,1 (3):349-353.
  • 3Fletcher JW,Djulbegovic B,Soares HP,et al.Recommendations on the Use of 18F-FDG PET in Oncology[J].J Nucl Med,2008,49(3):480-508.
  • 4Yamamoto Y,Nishiyama Y,Kameyama R,et al.Detection of Hepatocellular Carcinoma Using 11C-Choline PET:Comparison with 18F-FDG PET[J].J Nucl Med,2008,49(8):1245 1248.
  • 5Mazzaferro V,Regalia E,Doci R,et al.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J].N Engl J Med,1996,334(11):693-699.
  • 6Laurent S,Forge D,Port M,et al.Magnetic iron oxide nan oparticles:synthesis,stabilization,vectorization,physico chemical characterizations,and biological applications[J].Chem Rev,2008,108 (6):2064-2110.
  • 7Misri R,Saatchi K,H(a)feli UO,et al.Nanoprobes for hybrid SPECT/MR molecular imaging[J].Nanomedicine (Lond),2012,7(5):719-733.
  • 8Misri R,Meier D,Yung AC,et al.Development and evaluation of a dual-modality (MRI/SPECT) molecular imaging bioprobe[J].Nanomedicine,2012,8(6):1007-1016.
  • 9Lee CM,Jeong HJ,Kim EM,et al.Superparamagnetic iron oxide nanoparticles as a dual imaging probe for targeting hepatocytesin vivo[J].Magn Reson Med,2009,62(6):1440-1446.
  • 10Park YN,Kim YB,Yang KM,et al.Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis[J].Arch Pathol Lab Med,2000,124(7):1061-1065.

同被引文献3

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部